Impact of corticosteroids use on midterm sequelae in survivors of COVID-19 admitted to hospital : A prospective cohort study
© 2023 Wiley Periodicals LLC..
An understanding of the midterm sequelae in COVID-19 and their association with corticosteroids use are needed. Between March and July 2020, we evaluated 1227 survivors of COVID-19, 3 months posthospitalization, of whom 213 had received corticosteroids within 7 days of admission. Main outcome was any midterm sequelae (oxygen therapy, shortness of breath, one major clinical sign, two minor clinical signs or three minor symptoms). Association between corticosteroids use and midterm sequelae was assessed using inverse propensity-score weighting models. Our sample included 753 (61%) male patients, and 512 (42%) were older than 65 years. We found a higher rate of sequelae among users than nonusers of corticosteroids (42% vs. 35%, odds ratio [OR] 1.40 [1.16-1.69]). Midterm sequelae were more frequent in users of low-dose corticosteroids than nonusers (64% vs. 51%, OR 1.60 [1.10-2.32]), whereas no association between higher doses (≥20 mg/day equivalent of dexamethasone) and sequelae was evidenced (OR 0.95 [0.56-1.61]). Higher risk of sequelae with corticosteroids use was observed among subjects with propensity score below the 90th percentile. Our study suggest that corticosteroids use during hospitalization for COVID-19 is associated with higher risk of midterm sequelae.
| Errataetall: |
CommentIn: J Med Virol. 2023 Aug;95(8):e28988. - PMID 37503545 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:95 |
|---|---|
| Enthalten in: |
Journal of medical virology - 95(2023), 6 vom: 01. Juni, Seite e28819 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gault, Nathalie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 30.05.2023 Date Revised 02.08.2023 published: Print CommentIn: J Med Virol. 2023 Aug;95(8):e28988. - PMID 37503545 Citation Status MEDLINE |
|---|
| doi: |
10.1002/jmv.28819 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357489845 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357489845 | ||
| 003 | DE-627 | ||
| 005 | 20231226072714.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jmv.28819 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM357489845 | ||
| 035 | |a (NLM)37246784 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gault, Nathalie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of corticosteroids use on midterm sequelae in survivors of COVID-19 admitted to hospital |b A prospective cohort study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.05.2023 | ||
| 500 | |a Date Revised 02.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: J Med Virol. 2023 Aug;95(8):e28988. - PMID 37503545 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley Periodicals LLC. | ||
| 520 | |a An understanding of the midterm sequelae in COVID-19 and their association with corticosteroids use are needed. Between March and July 2020, we evaluated 1227 survivors of COVID-19, 3 months posthospitalization, of whom 213 had received corticosteroids within 7 days of admission. Main outcome was any midterm sequelae (oxygen therapy, shortness of breath, one major clinical sign, two minor clinical signs or three minor symptoms). Association between corticosteroids use and midterm sequelae was assessed using inverse propensity-score weighting models. Our sample included 753 (61%) male patients, and 512 (42%) were older than 65 years. We found a higher rate of sequelae among users than nonusers of corticosteroids (42% vs. 35%, odds ratio [OR] 1.40 [1.16-1.69]). Midterm sequelae were more frequent in users of low-dose corticosteroids than nonusers (64% vs. 51%, OR 1.60 [1.10-2.32]), whereas no association between higher doses (≥20 mg/day equivalent of dexamethasone) and sequelae was evidenced (OR 0.95 [0.56-1.61]). Higher risk of sequelae with corticosteroids use was observed among subjects with propensity score below the 90th percentile. Our study suggest that corticosteroids use during hospitalization for COVID-19 is associated with higher risk of midterm sequelae | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a cohort study | |
| 650 | 4 | |a corticosteroids | |
| 650 | 4 | |a propensity score | |
| 650 | 4 | |a sequelae | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 700 | 1 | |a Bachelet, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Laouénan, Cédric |e verfasserin |4 aut | |
| 700 | 1 | |a Borie, Raphaël |e verfasserin |4 aut | |
| 700 | 1 | |a Cracowski, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Poissy, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Faure, Karine |e verfasserin |4 aut | |
| 700 | 1 | |a Lainé, Fabrice |e verfasserin |4 aut | |
| 700 | 1 | |a Lefèvre, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Isnard, Margaux |e verfasserin |4 aut | |
| 700 | 1 | |a Patrier, Juliette |e verfasserin |4 aut | |
| 700 | 1 | |a Launay, Odile |e verfasserin |4 aut | |
| 700 | 1 | |a Costagliola, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosn, Jade |e verfasserin |4 aut | |
| 700 | 1 | |a Bouadma, Lila |e verfasserin |4 aut | |
| 700 | 0 | |a French COVID Cohort Study Group and The French COVID Investigators Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 95(2023), 6 vom: 01. Juni, Seite e28819 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:95 |g year:2023 |g number:6 |g day:01 |g month:06 |g pages:e28819 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.28819 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 95 |j 2023 |e 6 |b 01 |c 06 |h e28819 | ||